Patents by Inventor Evan Newbold

Evan Newbold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND MATERIALS FOR TREATING NEUROTOXICITY
    Publication number: 20220354834
    Abstract: This document relates to methods and materials for treating a mammal having neurotoxicity (e.g., chemotherapy-induced neurotoxicity). For example, one or more T-type calcium channel modulators (e.g., a composition including one or more T-type calcium channel modulators such as CX-8998) can be administered to a mammal having neurotoxicity to treat the mammal.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 10, 2022
    Inventors: Yuri MARICICH, Evan NEWBOLD, Guido CAVALETTI, Cristina MEREGALLI
  • Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
    Patent number: 11311522
    Abstract: This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: April 26, 2022
    Assignee: CAVION, INC.
    Inventors: Margaret S. Lee, Spyridon Papapetropoulos, Michelle S. Higgin, Muralikrishna Duvvuri, Bruce N. Rehlaender, Evan Newbold
  • TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE
    Publication number: 20220016095
    Abstract: This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 20, 2022
    Inventors: Margaret S. LEE, Spyridon PAPAPETROPOULOUS, Michelle S. HIGGIN, Muralikrishna DUVVURI, Bruce N. REHLAENDER, Evan NEWBOLD
  • METHODS FOR TREATING DRAVET SYNDROME
    Publication number: 20200163943
    Abstract: Provided herein are methods of treating Dravet syndrome that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.
    Type: Application
    Filed: April 26, 2018
    Publication date: May 28, 2020
    Applicant: Cavion, Inc.
    Inventors: Yuri Maricich, Evan Newbold